Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease

被引：29

作者：

Bannai, Ei ^{[1
]}

Yamashita, Hiroyuki ^{[1
]}

Kaneko, Shunta ^{[1
]}

Ueda, Yo ^{[1
]}

Ozaki, Takashi ^{[1
]}

Tsuchiya, Haruka ^{[1
]}

Takahashi, Yuko ^{[1
]}

Kaneko, Hiroshi ^{[1
]}

Kano, Toshikazu ^{[1
]}

Mimori, Akio ^{[1
]}

机构：

[1] Natl Ctr Global Hlth & Med, Div Rheumat Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan

来源：

MODERN RHEUMATOLOGY | 2016年 / 26卷 / 02期

关键词：

Adult-onset Still's disease; Tocilizumab; Macrophage activation syndrome; MACROPHAGE ACTIVATION SYNDROME; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; RECEPTOR ANTIBODY; IL-6; RECEPTOR; EFFICACY; INTERLEUKIN-6; AGENTS; TRIAL;

D O I：

10.3109/14397595.2014.899178

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To evaluate the effects of tocilizumab (TCZ) on adult-onset Still's disease (AOSD), we reviewed medical records of seven patients with refractory AOSD treated with TCZ at our institution. TCZ therapy might allow rapid corticosteroid tapering and help maintain remission status, that is, resolution of clinical symptoms and normalization of biomarkers such as CRP and ferritin. Patients, however, should be monitored for the development of macrophage activation syndrome when TCZ is administered for active AOSD.

引用

页码：297 / 301

页数：5

共 50 条

[1] Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence
de Boysson, Hubert
Fevrier, Jerome
Nicolle, Amelie
Auzary, Christophe
Geffray, Loik
CLINICAL RHEUMATOLOGY, 2013, 32 (01) : 141 - 147
[2] Tocilizumab for the treatment of adult-onset Still's disease
Castaneda, Santos
Martinez-Quintanilla, Dolores
Martin-Varillas, Jose L.
Garcia-Castaneda, Noelia
Atienza-Mateo, Belen
Gonzalez-Gay, Miguel A.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (04) : 273 - 286
[3] Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome
Kobayashi, Masafumi
Takahashi, Yuko
Yamashita, Hiroyuki
Kaneko, Hiroshi
Mimori, Akio
MODERN RHEUMATOLOGY, 2011, 21 (01) : 92 - 96
[4] Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD)
Yoshimura, M.
Makiyama, J.
Koga, T.
Miyashita, T.
Izumi, Y.
Torigoshi, T.
Motokawa, S.
Eguchi, K.
Migita, K.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (01) : 141 - 142
[5] Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases
Song, S. T.
Kim, J. J.
Lee, S.
Kim, H. A.
Lee, E. Y.
Shin, K. C.
Lee, J. H.
Lee, K. H.
Choi, S. T.
Cha, H. S.
Yoo, D. H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : S64 - S71
[6] Two Cases of Adult-onset Still's Disease Treated with Tocilizumab that Achieved Tocilizumab-free Remission
Kobayashi, Daisuke
Ito, Satoshi
Murasawa, Akira
Narita, Ichiei
Nakazono, Kiyoshi
INTERNAL MEDICINE, 2015, 54 (20) : 2675 - 2679
[7] Acquired Amegakaryocytic Thrombocytopenia in Adult-onset Still's Disease: Successful Combination Therapy with Tocilizumab and Cyclosporine
Ichikawa, Takanori
Shimojima, Yasuhiro
Otuki, Toshiaki
Ueno, Ken-ichi
Kishida, Dai
Sekijima, Yoshiki
INTERNAL MEDICINE, 2019, 58 (23) : 3473 - 3478
[8] Treatment of refractory adult-onset still's disease with tocilizumab: report of two cases and review of the literature
Thonhofer, Rene
Hiller, Manuela
Just, Horst
Trummer, Markus
Siegel, Cornelia
Dejaco, Christian
RHEUMATOLOGY INTERNATIONAL, 2011, 31 (12) : 1653 - 1656
[9] Tocilizumab in Adult-onset Still's Disease: the Israeli Experience
Elkayam, Ori
Jiries, Nizar
Dranitzki, Zvi
Kivity, Shay
Lidar, Merav
Levy, Ofer
Ablin, Jacob
Abu-Shakra, Mahmoud
Savargyl-Maman, Hagit
Padova, Hagit
Caspi, Dan
Rosner, Itzhak
JOURNAL OF RHEUMATOLOGY, 2014, 41 (02) : 244 - 247
[10] Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: A meta-analysis
Ma, Yubo
Wu, Meng
Zhang, Xu
Xia, Qing
Yang, Jiajia
Xu, Shengqian
Pan, Faming
MODERN RHEUMATOLOGY, 2018, 28 (05) : 849 - 857

← 1 2 3 4 5 →